|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
20
|
|
pubmed:dateCreated |
2006-5-29
|
|
pubmed:abstractText |
To determine the clinical effectiveness and cost-effectiveness of the administration of intravenous enzyme replacement therapy (ERT) to symptomatic patients for the prevention of long-term damage and symptoms in Fabry's disease and in mucopolysaccharidosis type 1 (MPS1).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1366-5278
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
iii-iv, ix-113
|
|
pubmed:meshHeading |
pubmed-meshheading:16729919-Adult,
pubmed-meshheading:16729919-Cost-Benefit Analysis,
pubmed-meshheading:16729919-Fabry Disease,
pubmed-meshheading:16729919-Female,
pubmed-meshheading:16729919-Great Britain,
pubmed-meshheading:16729919-Humans,
pubmed-meshheading:16729919-Iduronidase,
pubmed-meshheading:16729919-Male,
pubmed-meshheading:16729919-Middle Aged,
pubmed-meshheading:16729919-Mucopolysaccharidoses,
pubmed-meshheading:16729919-State Medicine,
pubmed-meshheading:16729919-Treatment Outcome,
pubmed-meshheading:16729919-alpha-Galactosidase
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry's disease and mucopolysaccharidosis type 1.
|
|
pubmed:affiliation |
Department of Public Health and Epidemiology, University of Birmingham, UK.
|
|
pubmed:publicationType |
Journal Article,
Review
|
